Response criteria in oncologic imaging: Review of traditional and new criteria

Temel Tirkes, Margaret A. Hollar, Mark Tann, Marc D. Kohli, M. Akisik, Kumar Sandrasegaran

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

There has been a proliferation and divergence of imaging-based tumor-specific response criteria over the past 3 decades whose purpose is to achieve objective assessment of treatment response in oncologic clinical trials. The World Health Organization (WHO) criteria, published in 1981, were the first response criteria and made use of bidimensional measurements of tumors. The Response Evaluation Criteria in Solid Tumors (RECIST) were created in 2000 and revised in 2009. The RECIST criteria made use of unidimensional measurements and addressed several pitfalls and limitations of the original WHO criteria. Both the WHO and RECIST criteria were developed during the era of cytotoxic chemotherapeutic agents and are still widely used. However, treatment strategies changed over the past decade, and the limitations of using tumor size alone in patients undergoing targeted therapy (including arbitrarily determined cutoff values to categorize tumor response and progression, lack of information about changes in tumor attenuation, inability to help distinguish viable tumor from nonviable components, and inconsistency of size measurements) necessitated revision of these criteria. More recent criteria that are used for targeted therapies include the Choi response criteria for gastrointestinal stromal tumor, modified RECIST criteria for hepatocellular carcinoma, and Immune-related Response Criteria for melanoma. The Cheson criteria and Positron Emission Tomography Response Criteria in Solid Tumors make use of positron emission tomography to provide functional information and thereby help determine tumor viability. As newer therapeutic agents and approaches become available, it may be necessary to further modify existing anatomy-based response-assessment methodologies, verify promising functional imaging methods in large prospective trials, and investigate new quantitative imaging technologies.

Original languageEnglish
Pages (from-to)1323-1341
Number of pages19
JournalRadiographics
Volume33
Issue number5
DOIs
StatePublished - Sep 2013

Fingerprint

Neoplasms
Positron-Emission Tomography
Therapeutics
Gastrointestinal Stromal Tumors
Cytotoxins
Hepatocellular Carcinoma
Melanoma
Anatomy
Clinical Trials
Technology
Response Evaluation Criteria in Solid Tumors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Response criteria in oncologic imaging : Review of traditional and new criteria. / Tirkes, Temel; Hollar, Margaret A.; Tann, Mark; Kohli, Marc D.; Akisik, M.; Sandrasegaran, Kumar.

In: Radiographics, Vol. 33, No. 5, 09.2013, p. 1323-1341.

Research output: Contribution to journalArticle

Tirkes, Temel ; Hollar, Margaret A. ; Tann, Mark ; Kohli, Marc D. ; Akisik, M. ; Sandrasegaran, Kumar. / Response criteria in oncologic imaging : Review of traditional and new criteria. In: Radiographics. 2013 ; Vol. 33, No. 5. pp. 1323-1341.
@article{479fed8c2a70460f836ad97074608ba2,
title = "Response criteria in oncologic imaging: Review of traditional and new criteria",
abstract = "There has been a proliferation and divergence of imaging-based tumor-specific response criteria over the past 3 decades whose purpose is to achieve objective assessment of treatment response in oncologic clinical trials. The World Health Organization (WHO) criteria, published in 1981, were the first response criteria and made use of bidimensional measurements of tumors. The Response Evaluation Criteria in Solid Tumors (RECIST) were created in 2000 and revised in 2009. The RECIST criteria made use of unidimensional measurements and addressed several pitfalls and limitations of the original WHO criteria. Both the WHO and RECIST criteria were developed during the era of cytotoxic chemotherapeutic agents and are still widely used. However, treatment strategies changed over the past decade, and the limitations of using tumor size alone in patients undergoing targeted therapy (including arbitrarily determined cutoff values to categorize tumor response and progression, lack of information about changes in tumor attenuation, inability to help distinguish viable tumor from nonviable components, and inconsistency of size measurements) necessitated revision of these criteria. More recent criteria that are used for targeted therapies include the Choi response criteria for gastrointestinal stromal tumor, modified RECIST criteria for hepatocellular carcinoma, and Immune-related Response Criteria for melanoma. The Cheson criteria and Positron Emission Tomography Response Criteria in Solid Tumors make use of positron emission tomography to provide functional information and thereby help determine tumor viability. As newer therapeutic agents and approaches become available, it may be necessary to further modify existing anatomy-based response-assessment methodologies, verify promising functional imaging methods in large prospective trials, and investigate new quantitative imaging technologies.",
author = "Temel Tirkes and Hollar, {Margaret A.} and Mark Tann and Kohli, {Marc D.} and M. Akisik and Kumar Sandrasegaran",
year = "2013",
month = "9",
doi = "10.1148/rg.335125214",
language = "English",
volume = "33",
pages = "1323--1341",
journal = "Radiographics",
issn = "0271-5333",
publisher = "Radiological Society of North America Inc.",
number = "5",

}

TY - JOUR

T1 - Response criteria in oncologic imaging

T2 - Review of traditional and new criteria

AU - Tirkes, Temel

AU - Hollar, Margaret A.

AU - Tann, Mark

AU - Kohli, Marc D.

AU - Akisik, M.

AU - Sandrasegaran, Kumar

PY - 2013/9

Y1 - 2013/9

N2 - There has been a proliferation and divergence of imaging-based tumor-specific response criteria over the past 3 decades whose purpose is to achieve objective assessment of treatment response in oncologic clinical trials. The World Health Organization (WHO) criteria, published in 1981, were the first response criteria and made use of bidimensional measurements of tumors. The Response Evaluation Criteria in Solid Tumors (RECIST) were created in 2000 and revised in 2009. The RECIST criteria made use of unidimensional measurements and addressed several pitfalls and limitations of the original WHO criteria. Both the WHO and RECIST criteria were developed during the era of cytotoxic chemotherapeutic agents and are still widely used. However, treatment strategies changed over the past decade, and the limitations of using tumor size alone in patients undergoing targeted therapy (including arbitrarily determined cutoff values to categorize tumor response and progression, lack of information about changes in tumor attenuation, inability to help distinguish viable tumor from nonviable components, and inconsistency of size measurements) necessitated revision of these criteria. More recent criteria that are used for targeted therapies include the Choi response criteria for gastrointestinal stromal tumor, modified RECIST criteria for hepatocellular carcinoma, and Immune-related Response Criteria for melanoma. The Cheson criteria and Positron Emission Tomography Response Criteria in Solid Tumors make use of positron emission tomography to provide functional information and thereby help determine tumor viability. As newer therapeutic agents and approaches become available, it may be necessary to further modify existing anatomy-based response-assessment methodologies, verify promising functional imaging methods in large prospective trials, and investigate new quantitative imaging technologies.

AB - There has been a proliferation and divergence of imaging-based tumor-specific response criteria over the past 3 decades whose purpose is to achieve objective assessment of treatment response in oncologic clinical trials. The World Health Organization (WHO) criteria, published in 1981, were the first response criteria and made use of bidimensional measurements of tumors. The Response Evaluation Criteria in Solid Tumors (RECIST) were created in 2000 and revised in 2009. The RECIST criteria made use of unidimensional measurements and addressed several pitfalls and limitations of the original WHO criteria. Both the WHO and RECIST criteria were developed during the era of cytotoxic chemotherapeutic agents and are still widely used. However, treatment strategies changed over the past decade, and the limitations of using tumor size alone in patients undergoing targeted therapy (including arbitrarily determined cutoff values to categorize tumor response and progression, lack of information about changes in tumor attenuation, inability to help distinguish viable tumor from nonviable components, and inconsistency of size measurements) necessitated revision of these criteria. More recent criteria that are used for targeted therapies include the Choi response criteria for gastrointestinal stromal tumor, modified RECIST criteria for hepatocellular carcinoma, and Immune-related Response Criteria for melanoma. The Cheson criteria and Positron Emission Tomography Response Criteria in Solid Tumors make use of positron emission tomography to provide functional information and thereby help determine tumor viability. As newer therapeutic agents and approaches become available, it may be necessary to further modify existing anatomy-based response-assessment methodologies, verify promising functional imaging methods in large prospective trials, and investigate new quantitative imaging technologies.

UR - http://www.scopus.com/inward/record.url?scp=84884400552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884400552&partnerID=8YFLogxK

U2 - 10.1148/rg.335125214

DO - 10.1148/rg.335125214

M3 - Article

C2 - 24025927

AN - SCOPUS:84884400552

VL - 33

SP - 1323

EP - 1341

JO - Radiographics

JF - Radiographics

SN - 0271-5333

IS - 5

ER -